Philip, Sephy

Increased residual cardiovascular risk in patients with diabetes and high versus normal triglycerides despite statin‐controlled LDL cholesterol

Nichols, G. A., Philip, S., Reynolds, K., Granowitz, C. B., & Fazio, S. (2019) · Diabetes, Obesity and Metabolism

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 125

High Triglycerides Are Associated With Increased Cardiovascular Events, Medical Costs, and Resource Use: A Real‐World Administrative Claims Analysis of Statin‐Treated Patients With High Residual Cardiovascular Risk

Toth, P. P., Granowitz, C., Hull, M., Liassou, D., Anderson, A., & Philip, S. (2018) · Journal of the American Heart Association

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 117

Mineral oil: safety and use as placebo in REDUCE-IT and other clinical studies

Olshansky, B., Chung, M. K., Budoff, M. J., Philip, S., Jiao, L., Doyle, Jr., Copland, C., Giaquinto, A., Juliano, R. A., & Bhatt, D. L. (2020) · European Heart Journal Supplements

Fatty Acid Research and HealthStatistical Methods in Clinical Trials

Cited by 103

Increased Cardiovascular Risk in Hypertriglyceridemic Patients With Statin-Controlled LDL Cholesterol

Nichols, G. A., Philip, S., Reynolds, K., Granowitz, C. B., & Fazio, S. (2018) · The Journal of Clinical Endocrinology & Metabolism

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 102

Hypertriglyceridemia in statin-treated US adults: the National Health and Nutrition Examination Survey

Fan, W., Philip, S., Granowitz, C., Toth, P. P., & Wong, N. D. (2019) · Journal of Clinical Lipidology

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 67

Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies

Ballantyne, C. M., Bays, H. E., Philip, S., Doyle, R. T., Braeckman, R. A., Stirtan, W. G., Soni, P. N., & Juliano, R. A. (2016) · Atherosclerosis

Fatty Acid Research and HealthLipoproteins and Cardiovascular Health

Cited by 52

Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on plasma apolipoprotein C-III levels in patients from the MARINE and ANCHOR studies

Ballantyne, C. M., Bays, H. E., Braeckman, R. A., Philip, S., Stirtan, W. G., Doyle, R. T., Soni, P. N., & Juliano, R. A. (2016) · Journal of Clinical Lipidology

Fatty Acid Research and HealthLipoproteins and Cardiovascular Health

Cited by 47

Icosapent ethyl: Eicosapentaenoic acid concentration and triglyceride-lowering effects across clinical studies

Bays, H. E., Ballantyne, C. M., Doyle, R. T., Juliano, R. A., & Philip, S. (2016) · Prostaglandins & Other Lipid Mediators

Fatty Acid Research and HealthLipid metabolism and disorders

Cited by 43

Triglyceride levels and residual risk of atherosclerotic cardiovascular disease events and death in adults receiving statin therapy for primary or secondary prevention: insights from the KP REACH study

Ambrosy, A. P., Yang, J., Sung, S. H., Allen, A. R., Fitzpatrick, J. K., Rana, J. S., Wagner, J., Philip, S., Abrahamson, D., Granowitz, C., et al. (2021) · Journal of the American Heart Association

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 32

Lipid effects of icosapent ethyl in women with diabetes mellitus and persistent high triglycerides on statin treatment: ANCHOR trial subanalysis

Brinton, E. A., Ballantyne, C. M., Guyton, J. R., Philip, S., Doyle, R. T., Juliano, R. A., & Mosca, L. (2018) · Journal of Women's Health

Fatty Acid Research and HealthLipoproteins and Cardiovascular Health

Cited by 13

Prevalence of United States adults with triglycerides ≥ 135 mg/dL: NHANES 2007–2014

Fan, W., Philip, S., Toth, P. P., Granowitz, C., & Wong, N. D. (2019) · Cardiology Journal

Lipid metabolism and disordersDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 6